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Chronic wasting disease (CWD), a transmissible prion disease
that affects elk and deer, poses new challenges to animal and human
health. Although the transmission of CWD to humans has not been
proven, it remains a possibility. If this were to occur, it is important
to knowwhether the “acquired” human prion disease would show a
phenotype including the scrapie prion protein (PrPSc) features that
differ from those associated with human sporadic prion disease. In
this study, we have compared the pathological profiles and PrPSc
characteristics in brains of CWD-affected elk and deerwith those in
subjects with sporadic Creutzfeldt-Jakob disease (CJD), as well as
CJD-affected subjects whomight have been exposed to CWD, using
histopathology, immunohistochemistry, immunoblotting, confor-
mation stability assay, and N-terminal protein sequencing. Spongi-
form changes and intense PrPSc staining were present in several
brain regions of CWD-affected animals. Immunoblotting revealed
three proteinase K (PK)-resistant bands in CWD, representing dif-
ferent glycoforms of PrPSc. The unglycosylated PK-resistant PrPSc
ofCWDmigrated at 21kDawith anelectrophoreticmobility similar
to that of type 1 human PrPSc present in sporadic CJD affecting
subjects homozygous for methionine at codon 129 (sCJDMM1).
N-terminal sequencing showed that the PK cleavage site of PrPSc in
CWD occurred at residues 82 and 78, similar to that of PrPSc in
sCJDMM1. Conformation stability assay also showed no significant
difference between elk CWDPrPSc and the PrPSc species associated
with sCJDMM1. However, there was a major difference in glyco-
form ratio of PrPSc between CWD and sCJDMM1 affecting both
subjects potentially exposed to CWD and non-exposed subjects.
Moreover, PrPSc of CWD exhibited a distinct constellation of gly-
coforms distinguishable from that of sCJDMM1 in two-dimen-
sional immunoblots. These findings underline the importance of
detailed PrPSc characterization in trying to detect novel forms of
acquired prion disease.
Chronic wasting disease (CWD),2 first described in 1967, was identi-
fied in 1977 as a transmissible spongiform encephalopathy or prion
disease that affects both captive and free-ranging cervids (1, 2). Three
species are known to be affected, mule deer (Odocoileus hemionus),
white-tailed deer (O. virginianus), and RockyMountain elk (Cervus ela-
phus nelsoni) (3).
In addition to progressive loss of bodyweight, CWD is clinically char-
acterized by abnormal behavior, polydipsia, hypersalivation, and occa-
sionally ataxia and tremor (2, 4). The major histopathological features
include spongiform degeneration, astrogliosis, and neuronal loss, as in
most other forms of prion disease (2, 4). However, in CWD these lesions
are reported to have a distinct distribution (5, 6). In the central nervous
system, the spongiform degeneration is apparently most prominent in
subcortical regions, including the thalamus and hypothalamus, lower
brain stem, cerebellum, and spinal cord, whereas the cerebral cortex is
less affected or unaffected (5, 6). Kuru plaques, often surrounded by
vacuoles as in the “florid” plaques of variant Creutzfeldt-Jakob disease
(vCJD), the human prion disease acquired from the consumption of
prion-contaminated beef, have been convincingly shown only in captive
mule deer (7, 8). The disease-associated prion protein isoform (PrPSc) is
detected by immunohistochemistry with a topography similar to, but
wider than, that of the histological lesions (5–7). The immunostained
PrPSc deposits have been reported to be dispersed in the parenchyma
with a punctate or “synaptic” pattern, in addition to the loose clusters
forming the so-called plaque-like pattern as well as packed clusters in
the kuru plaques (7–11). The PrPSc deposits may line along the surface
of neuronal cell bodies and processes as well as in the parenchyma
immediately surrounding small vessels (7). Consistent PrPSc immuno-
staining has also been reported in the peripheral nervous system, espe-
cially the vagus and sympathetic nerves, lymphoreticular system, and
visceral organs (5, 10).
CWD appears to be freely transmitted among the three susceptible
species of cervids by direct or indirect horizontal contact (2, 4, 11). The
oral port of infection through forage contaminated by feces or saliva
from infected animals is considered the most likely mode of transmis-
sion (2–4, 11). Intra-species transmissibility and increased surveillance
have contributed to the discovery that geographic distribution and
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prevalence of CWD are greater than previously suspected (2–4). In
free-ranging and captive animals, CWD has now been detected in four-
teen states in the United States and in two Canadian provinces, with a
prevalence of up to 20% (2, 4, 12). Furthermore, CWD has been trans-
mitted to a number of experimental animals, including laboratorymice,
ferrets, mink, goats, and cattle (13, 14). The expanded geographic dis-
tribution and increased prevalence as well as the infectivity of CWD
have raised questions concerning CWD transmissibility to humans.
These questions are particularly alarming in North America where
almost all the CWD-affected animals have been observed and a large
number of hunters and their families regularly consume cervid meat.
Although prion disease has been demonstrated in at least 27 hunters or
their family members, as a group these cases were heterogeneous in
terms of the clinical and pathological phenotypes, the PrP genotype, and
the PrPSc subtype (15).3 Furthermore, the “hunter” cases appeared to fit
rather well in the known subtypes of human prion disease (16). How-
ever, the phenotype of the human prion disease that might be acquired
fromCWD is not known; itmightmimic any of the subtypes of sporadic
CJD, making the detection of this hypothetical “CWD-acquired CJD”
difficult. Thus far, the findings with the CJD in the hunter cases (15)
contrast with the reports on vCJD, where affected cases have highly
homogeneous features (17, 18). The homogeneity of vCJD has been
attributed to the exposure of the affected individuals to the same type of
PrPSc or prion strain associated with bovine spongiform encephalopa-
thy (BSE) (19). Indeed, features of the BSE-associated PrPSc are repro-
duced in vCJD (20). By analogy, it is likely that the possible CWD-
acquired CJD may reproduce the features of the PrPSc associated with
CWD. To gain insights into important pathological features andmolec-
ular characteristics of PrPSc in CWD-affected elk and deer, we have
carried out a comparative study of the histopathological, immunohisto-
chemical, and PrPSc characteristics of CWD and sporadic CJD subjects
as well as CJD-affected subjects whomight have been exposed to CWD.
MATERIALS ANDMETHODS
Reagents and Antibodies—All chemicals were purchased from Sigma
unless specified otherwise. Immobilized pHgradient strips (pH3–10, 11
cm long), ampholine pH 3–10, and reagents for enhanced chemilumi-
nescence were from Amersham Biosciences. Mouse monoclonal anti-
bodies (mAb) against PrP 8H4 (21) and 3F4 (Signet Laboratories, Ded-
ham, MA) were used in this study.
Brain Tissues—Tissue samples from free-ranging animals were col-
lected from the wild, including seven mule deer (O. hemionus), one
white-tailed deer (O. virginianus), and six Rocky Mountain elk (C. ela-
phus nelsoni). Brain tissues were stored at80 °C until use. Brains from
animals affected byCWDwere diagnosed and characterized by histopa-
thology, immunohistochemistry, and immunoblotting. Human brain
tissue was processed and characterized as previously reported (16, 22).
Brain tissue was obtained from five cases of elk and deer hunters who
also had a history of regularly consuming elk and deermeat; one of these
cases was also known to hunt in an area where CWDhas been proven to
be endemic. They were all homozygous methionine at codon 129, had
PrPSc type 1 and a phenotype consistentwithCJD,with an average age of
onset of 71 years (range 61–84 years) and an average duration of 5
months (range 2–5 months). Sporadic cases of human CJD having
either PrPSc type 1 or 2 were also used.
Molecular Genetics—Genomic DNA was extracted from frozen
brain tissues. The open reading frame of cervid PrP gene was sequenced
from both alleles as described previously (16).
Histology and Immunohistochemistry—Cervid brains removed at
autopsy were fixed in formalin and sampled. Tissue blocks were kept in
98% formic acid for 1 h, followed by a second formalin fixation and
paraffin embedding. They were then sectioned and prepared for histo-
logical examination according to standard techniques. For PrPSc immu-
nohistochemistry, sections were immersed in 1.5 mM hydrochloric acid
andmicrowaved for 15min at 20%power. Sectionswere then rinsed and
incubated for 2 h in a 4 M guanidine thiocyanate solution at 4 °C. The
endogenous peroxidase was blocked by incubation with 8% hydrogen
peroxide in distilled water for 10 min. After rinsing, sections were incu-
bated with mAb 8H4 at 1:600, washed, and incubated with Dako Cyto-
mation Envision plus Dual Link System Peroxidase for 30 min. Di-
aminobenzidine tetrahydrochloride was used to visualize the
immunoreactivity.
One- and Two-dimensional Immunoblot—Cervid and human brain
homogenates (10%, w/v) were made in ice-cold lysis buffer (100 mM
NaCl, 10 mM EDTA, 0.5% Nonidet P 40, 0.5% sodium deoxycholate, 10
mM Tris-HCl, pH 7.5), followed by centrifugation at 1,000  g for 10
min at 4 °C to remove debris. An aliquot of the brain homogenate was
digested with proteinase K (PK) at 50 g/ml for 1 h at 37 °C. The diges-
tion was terminated by the addition of 3 mM phenylmethylsulfonyl flu-
oride and an equal volume of 2 gel loading buffer (6% sodium dodecyl
sulfate (SDS), 5% -mercaptoethanol, 4 mM EDTA, 20% glycerol, 125
mM Tris-HCl, pH 6.8), followed by boiling for 10 min. In some cases,
deglycosylation of proteins was performed following precipitation with
5 volumes ofmethanol. Themethanol-precipitated proteins were dena-
tured and incubated with recombinant peptideN-glycosidase F accord-
ing to the manufacturer’s protocol (Roche Applied Science). Deglyco-
sylated sampleswere thenmixedwith an equal volume of 2 gel loading
buffer and boiled for 10min. Proteins were separated by SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) using 12% Tris-glycine mini-
gels (Invitrogen). PrPSc was also characterized by two-dimensional gel
electrophoresis as described previously (23). Briefly, PK-treated samples
were boiled in gel loading buffer, followed by precipitation by 9 volumes
of chilled acetone at 20 °C for 2 h, followed by centrifugation at
16,000  g for 15 min at 4 °C. The pellets were resuspended in 10%
trichloroacetic acid for 2 h at room temperature and were centrifuged
again. The pellets were resuspended in 200l of rehydration buffer (7 M
urea, 2 M thiourea, 2% CHAPS, 0.5% ampholine pH 3–10, and trace
amount of bromphenol blue) andwere loaded onto the immobilized pH
gradient strips for rehydration at 50 V for 14 h. The first-dimensional
isoelectric focusing was performed on the rehydrated immobilized pH
gradient strips for a total of 40 kVh using a Bio-Rad Protean isoelectric
focusing cell. For the second-dimension SDS-PAGE, the focused immo-
bilized pH gradient strips were equilibrated for 15 min each in equili-
bration buffer A (6 M urea, 2% SDS, 20% glycerol, 2% dithiothreitol, and
0.375 M Tris-HCl, pH 8.8) and then in equilibration buffer B (6 M urea,
2% SDS, 20% glycerol, 2.5% iodoacetamide, and 0.375 M Tris-HCl, pH
8.8). The equilibrated strips were loaded onto 15% Tris-glycine SDS-
PAGE gels (Bio-Rad Criterion gels). Electrophoresis was conducted at
120 V. The mAb 8H4 were used for all the two-dimensional immuno-
blots, except for Fig. 3B, which was immunoreacted with mAb 3F4.
Proteins on the SDS-PAGE gels were transferred onto polyvinylidene
difluoride membranes at 70 V for 2 h at 4 °C. The membranes were
blocked with 10% nonfat milk in TBST (150 mM NaCl, 0.1% Tween 20,
10 mM Tris-HCl, pH 7.6) overnight at 4 °C prior to incubation with
either anti-PrP mAb 8H4 (1:10,000) or 3F4 (1:50,000). Following four
washes with TBST, the polyvinylidene difluoride membranes were
incubatedwith sheep anti-mouse IgG conjugatedwith horseradish per-
oxidase (Amersham Biosciences). The PrP bands were visualized on3 S. G. Chen and P. Gambetti, unpublished data.
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Kodak X-Omat films by enhanced chemiluminescence (ECL Plus kit;
Amersham Biosciences).
Conformational Stability Assay of PrPSc—Aliquots of brain homoge-
nates were incubated with various concentrations of guanidine hydro-
chloride (GdnHCl) from 0 to 3.0 M (24, 25). GdnHCl stock solutions
were prepared by dilution in water from an 8 M solution. Following
incubation for 1 h at room temperature, all samples were precipitated in
pre-chilledmethanol at20 °C for 2 h and centrifuged at 16,000 g for
20 min at 4 °C. Pellets were resuspended in lysis buffer and treated with
100 g/ml PK for 1 h at 37 °C. The reaction was stopped by adding
phenylmethylsulfonyl fluoride (3 mM) and gel loading buffer and boiled
for 10 min. The samples were used for immunoblotting with 8H4.
Purification of PrPSc from CWD-affected Brains—Brain tissues (5–10
g) were used for purification of PK-resistant PrPSc core fragments
according to the publishedmethod (26), asmodified (27). After the final
sedimentation of PK-digested PrPSc by ultracentrifugation, the pellets
were denatured followed by deglycosylation withN-glycosidase F. PrPSc
were purified further by micropreparative continuous elution SDS-
PAGE (14% gel, Mini Prep Cell apparatus; Bio-Rad). Proteins were
eluted at a flow rate of 70 l/min and collected into 400-l fractions.
The fractions containing PrPSc as detected by immunoblotting with
mAb 8H4 were pooled and lyophilized.
N-terminal Protein Sequencing—Purified PK-resistant PrPSc in the
pooled fractions as described above were separated by 12% Tris-glycine
SDS-PAGE mini-gels (Invitrogen), transferred onto Problott mem-
branes (Applied Biosystems, Foster City, CA), and visualized by Coo-
massie Blue staining. N-terminal protein sequencing by automated
Edman degradation was performed as described previously (22) at the
ProSeqMicrosequencing Facility (Boxford,MA) using the Applied Bio-
systems 477A Protein Sequencer. N-terminal sequencing typically pro-
ceeded for 20–25 cycles. N-terminal sequences of PrPSc were deter-
mined by alignment of the experimentally determined amino acids at
each cycle with the translated human PrP sequence (Swiss-Prot acces-
sion number P04156).
RESULTS
Histopathology of CWD—The cerebral cortex and basal ganglia of the
elk with CWD show minimal fine spongiform degeneration and astro-
gliosis with focal distribution. The spongiform degeneration with astro-
gliosis is more prominent in the thalamus where it forms clusters of
coarse vacuoles. Fine spongiosis, often in small clusters, is present in the
molecular layer of the cerebellum, dorsal nuclei of the pons, and in the
substantia gelatinosa of the spinal cord (Fig. 1A). Occasional large neu-
rons in various nuclei of the pons show a vacuole (Fig. 1A). No kuru or
multicore plaques are detected. Neuronal loss and astrogliosis are min-
imal except for the molecular layer of the cerebellum, which shows
rarefaction of granule cells with no indication of apoptosis.
Immunohistochemistry—PrPSc immunostaining of the elk brain tis-
sue affected by CWD shows rounded granular aggregates of various
sizes and densities corresponding to the so-called plaque-like pattern
(Fig. 1B). Occasionally small plaque-like formations are arranged in
short rows or the immunostain is linear, consistent with staining of cell
processes. When the plaque-like deposits are confluent and loose, the
immunostaining may become similar to the synaptic pattern. Occa-
sional focal areas of coarse PrPSc immunostaining pattern apparently
associated with coarse spongiosis are also present. In addition, there is
occasional staining around intra-parenchymal vessels. The PrPSc
immunostaining is consistently present in the cerebral cortex, basal
ganglia, and thalamus. In the cerebellum the immunostaining is present
in both molecular and granule cell layers as well as in the dentate
nucleus. In the pons it is widespread over gray structures, whereas in the
spinal cord it is generally confined to the dorsal part of the dorsal horns.
Detection and Typing of PrPSc in CWD—Brain samples from a total of
sevenmule deer, one white tail deer, and six elk affected by CWD tested
positive for PK-resistant PrPSc on immunoblots. PrPSc characteristics of
CWD-affected animals were compared with those of sporadic CJD
cases associated with either PrPSc type 1 or type 2 (using nomenclature
of Parchi et al. (28)). Representative results from three mule deer, one
white tail deer, and three elk samples are shown in Fig. 2. The bands of
the unglycosylated form of PK-resistant PrPSc species from mule deer,
white tail deer, and elk all migrate to21 kDa andmatch the gel mobil-
ity of human PrPSc type 1, but not type 2 (Fig. 2, A and B). However, the
PrPSc associated with all three species of cervids differs significantly in
the ratio of the three glycoforms from the humanPrPSc type 1 associated
with sCJD affecting subjects who were homozygous for methionine at
codon 129 (sCJDMM1, Ref. 16) (Fig. 2C). In the PrPSc type 1 associated
with sCJDMM1, the monoglycosylated form is predominant, account-
ing for 44–45% of all the glycoforms, whereas the diglycosylated and
unglycosylated account for 21–24 and 31–35%, respectively (16). In
contrast, both elk and mule deer PrPSc species show the prevalence of
the diglycosylated, representing 47–50%of the total, whereas themono-
glycosylated and unglycosylated forms represent 30–33 and 20%,
FIGURE 1.Histopathology and immunohistochemistry of PrPSc in the brain stem of
elk affected by CWD. A, prominent spongiform degeneration with an intra-neuronal
vacuole (arrow) (Pons; hematoxylin and eosin). B, immunohistochemistry demonstrates
amyloid plaque-like PrPSc deposition(Pons; mAb 8H4).
PrPSc in CWD and CJD
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respectively (Fig. 2C). This PrPSc glycoform ratio of CWD is similar to
that of BSE and variant CJD (20).
Two-dimensional Immunoblot—We further compared the PK-re-
sistant PrPSc species associated with CWD of mule deer, white tail deer,
and elkwith that of sCJDMM1using two-dimensional gel electrophore-
sis. All gel profiles show three rows of well resolved spots. However, the
molecular mass, representation, and number of these spots vary
between the cervid and sCJDMM1 samples (Fig. 3). In CWD prepara-
tions not treated with N-glycosidase, the upper row migrates between
29–30 kDa as comparedwith the upper row in sCJDpreparations that
is detectable between 27 and 29.5 kDa. Furthermore, the upper row
includes at least 8 spots, which migrate between pH 8.3 and 5.3 of the
gradient in the CWD preparations, whereas there are 9 spots in
sCJDMM1 that migrate between pH 6.7 and 5.0. The middle row
includes at least 9 spots between pH 9.0 and 5.7 in CWD and at least 8
spots between pH 7.0 and 5.0 in sCJDMM1. The molecular mass range
of the middle row also is different, being27.5–25.0 kDa in CWD and
26.5–24 kDa in sCJDMM1. The third row also differs as it includes at
least three spots of 21.5–22.5 kDa distributed between pH 9.0 and 7.0 in
CWD,whereas at least four spots of22 kDa are seen in sCJDMM1 that
migrate between pH 8.0 and 6.7. The two-dimensional gel also confirms
that, although in sCJDMM1 the middle and lower rows are much more
prominent than the upper row, the opposite happens in CWD, where
the upper row is much better represented than the other two. The
profiles of the PK-resistant PrPSc core proteins obtained following deg-
lycosylation by N-glycosidase confirm that the PrPSc unglycosylated
core proteins of sCJDMM1 and CWD have similar molecular weights
(Fig. 3, B, D, F, H). However, in CWD, deglycosylated PrPSc species are
more basic than that in sCJDMM1. This difference is especially notice-
able between sCJDMM1 and mule deer and white tail deer PrPSc prep-
arations. Whereas in sCJDMM1 PrPSc distributes over the 5.8–8.5
pH gradient with the major spots located between pH 5.9 and 6.8, in
CWD PrPSc migrates between pH 6.5 and 9.5 with conspicuous spots
located at pH 8.5–9.5 (Fig. 3, B, D, F). The number of the spots is also
different with six detectable spots in sCJDMM1 and 5 and 7 in the mule
and white tail deer. The PK-resistant PrPSc core of elk CWD displays a
pH gradient distribution between 5.8 and 8.5, similar to that of
sCJDMM1, but the spots appear to form a quite different pattern (Fig. 3,
B and H).
Conformational Stability Assay of PrPSc—Conformational stability
assay has been used to distinguish different prion strains based on the
concentration of GdnHCl needed to denature the PK-resistant PrPSc
present in the individual strains. GdnHCl-dependent PrPSc denatur-
ation is determined by the fraction of PrPSc that is rendered PK sensitive
following GdnHCl treatment (24, 25, 29). The GdnHCl concentration
required to make half of the total PrPSc sensitive to PK digestion
(GdnHCl 1⁄2) is used as a measurement of the relative conformational
stability of PrPSc. The GdnHCl 1⁄2 was1.62 0.01 M (n 3) for PrPSc
from CWD-affected elk and 1.84  0.17 M (n  4) for PrPSc from
sCJDMM1 (Fig. 4), but the difference was not statistically significant
(p 0.12, two-tail t-test). Our data indicate that there is no significant
difference in the conformational stability between the two PrPSc species.
N-terminal Sequencing—Additional experiments have been carried
out to further characterize the protein core of the PK-resistant PrPSc
fragment associated with CWD and compare it with those of human
PrPSc type 1. In two elk affected by CWD, we detected two major co-
existing N-terminal sequences of PrPSc following treatment with PK
(Fig. 5A), as previously observed in PrPSc type 1 associated with CJD
(22). The N termini of the two fragments are at residues Gly-82 and
Gly-78 in both CWD (Fig. 5A) and sCJDMM1 (Fig. 5B). In contrast, the
N termini of the two major PK-resistant fragments of the PrPSc associ-
ated with sCJDVV1 are at residues Gly-86 and Gly-82 (ref 22). These
findings confirm that themain PK cleavage sites of PrPSc are the same in
CWD and sCJDMM1 but different from those of sCJDVV1.
PrPSc from the Hunter Cases—Immunoblots of brain homogenates
from five hunter cases who had a genotype of MM and carried PrPSc
type 1 show gel migration of the PK-resistant PrPSc fragment at 21 kDa,
indistinguishable from that of sCJDMM1 andCWD (Fig. 6A). However,
the glycoform ratio of each of these cases matches that of sCJDMM1
(Fig. 6B), but not CWD (Fig. 2C).
DISCUSSION
Consistent with previous studies, we observed that spongiform
degeneration involving the neuropil as well as the cell body of neurons is
the histopathological hallmark of CWD in free-ranging elk, whereas
astrogliosis and neuronal loss are generally minimal. These lesions pref-
erentially affect subcortical regions, especially the thalamus and the
lower brain stem where some anatomical structures are preferentially
FIGURE 2. Immunoblots and glycoform ratios of PK-resistant PrPSc from CWD-af-
fectedelkanddeerandsCJDassociatedwithPrPSc types1and2.Humanbrain tissue
was obtained from subjectswith sCJDMM1and sCJDMM2according to the classification
of Parchi et al. (16). Brain homogenates were treated with PK, followed by SDS/PAGE
(12%gel) and immunoblottingusingmAb8H4. Enzymatic deglycosylationof PK-treated
samples was performed using N-glycosidase F. A, the PK digest equivalent to 10 l of
10% brain homogenates was loaded on SDS/PAGE gels. The PK-resistant PrPSc was
detected as a triplet of bands representing diglycosylated (F), monoglycosylated (E),
and unglycosylated () forms. B, following deglycosylationwithN-glycosidase F,mainly
unglycosylated ()PrPSc was detected. PK-resistant PrPSc in CWD co-migrates with
human PrPSc type 1 as demonstrated by the alignment of the unglycosylated bands ()
in panels A and B. C, three specimens of CWD-affected elk andmule deer were subjected
to immunoblotting as in panel A except that the amount of the PK digest loaded was
adjusted to similar intensity of PrPSc signals to assist the glycoformanalysis by densitom-
etry. The immunoblots were examined by densitometry to determine the ratio of digly-
cosylated (Diglyc), monoglycosylated (Monoglyc), and unglycosylated (Unglyc) forms of
PrPSc expressed as percentage of the total (mean  S.D.). Data for sCJDMM1 were
obtained from Parchi et al. (16).
PrPSc in CWD and CJD
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affected. The immunostaining shows a PrPSc distribution in loose clus-
ters of granules of different sizes, a pattern commonly defined as plaque
like. Other patterns such as perivascular and perineuronal arrange-
ments are occasionally seen. PrPSc has a wider distribution than the
spongiform degeneration, so cerebral cortex and cerebellum that show
minimal spongiform degeneration are relatively well immunostained
for PrPSc.
The type and distribution of the histological lesions and of the PrPSc
immunostaining in the cervid samples are different from those observed
in human prion diseases. However, the lack of similarity between CWD
and the human diseasemay be possible even if a subtype of CJD believed
to be sporadic is actually acquired from CWD. Overwhelming evidence
indicates that vCJD is caused by the transmission of BSE to humans (30,
31). Therefore, comparing BSE with vCJD may provide guidance on
how to approach the issue of possible transmission of CWD to humans.
The histopathology and the PrPSc immunohistochemistry of BSE are
different from those of vCJD in the type and topography of the lesions as
well as the pattern of the PrPSc immunostaining (32, 33). In BSE the
lesions are most prominent in subcortical structures of the brain, espe-
cially basal ganglia, thalamus, hypothalamus, and selected regions of
brain stem and spinal cord, whereas the cerebral and cerebellar cortices
areminimally affected (33). Vacuole formation in the neuronal cell body
is a prominent lesion in BSE, whereas kuru plaques are lacking (33). In
contrast, vCJD is characterized by severe involvement of cerebral and
cerebellar cortices and the presence of kuru plaques surrounded by
vacuoles called florid plaques (32). Consistent with the different his-
topathology, PrPSc immunostaining in BSE is distributed as thick gran-
ules widespread in the neuropil but often with a perineuronal and
perivascular distribution (33), whereas in vCJD the PrPSc immunohis-
tochemistry is dominated by the intense staining of the kuru plaques.
Contrary to the histopathology and immunohistochemistry, the char-
acteristics of the PrPSc are fairly similar in BSE and vCJD (34): both PrPSc
species are type 2 and have similar glycoform ratios (32). Assuming that
if CWD is transmitted to humans it would follow the BSE-to-vCJD
pattern of disease conversion in which histopathology and PrPSc immu-
nostaining change but the basic characteristics of PrPSc are conserved,
we have compared in detail the characteristics of the PrPSc associated
with CWD with those of the PrPSc species associated with sCJD as well
as with CJD in individuals who may have been exposed to CWD.
Sporadic prion disease can be classified into five distinct subtypes of
sCJD and sporadic fatal insomnia, based on themethionine/valine poly-
morphic genotype at codon 129 of the PrP gene and the two conformers
(types 1 and 2) of the brain PrPSc (16, 28). PrPSc types 1 and 2 are
distinguished because, following treatment with PK, their protease-re-
sistant and unglycosylated fragments migrate to 21 and 19 kDa on
SDS-PAGE gels, respectively (28, 35). The distinct gel mobility is the
result of the different size of the PrPSc fragments generated by the PK
treatment, which cleaves the two PrPSc types at different sites, likely
because the twoPrPSc types have distinct conformations (22).Of the five
subtypes of sCJD, two are associated with PrPSc type 1 (16). The first
subtype includes patientswho are homozygous formethionine (MM)or
heterozygous methionine/valine (MV) at codon 129, identified as
sCJDMM1 and sCJDMV1, respectively; the patients of the second sub-
type, identified as sCJDVV1, are homozygous valine at codon 129 (16).
We have compared in detail deer and elk PrPSc only with the human
PrPSc type 1 associated with sCJDMM1 because the gel mobility and N
terminus following PK cleavage of the PrPSc associated with CWD are
indistinguishable in elk, mule deer, and white tail deer and match most
FIGURE 3. Two-dimensional maps of PK-resist-
ant PrPSc in brains of CWD-affected cervids and
sCJDMM1.A and B, sCJDMM1;C andD, mule deer;
E and F, white tail deer; G and H, elk. A, C, E and G,
N-glycosidase F untreated; B,D, F andH,N-glycosi-
dase treated. Three sets of spots are seen in the
two-dimensional blots of all theN-glycosidase-un-
treated PrPSc species from both sCJD and CWD (A,
C, E, and G). The spots formed by the cervid PrPSc
extend more toward the basic part of the pH gra-
dient (3.0–10.0) than those of sCJDMM1 PrPSc
(compare panel A with C, E, and G). Note the rela-
tive overrepresentation of the diglycosylated and
the underrepresentation of the unglycosylated
form in cervid PrPSc as compared with sCJDMM1
PrPSc (A,C,E, andG). ThedeglycosylatedPrPSc from
the mule and white tail deer migrates toward the
more basic part of the pH gradient (D and F),
whereas the pHmobility of the deglycosylated elk
PrPSc is more similar to that of the sCJDMM1 PrPSc
(B and H). The position of molecular mass markers
(in kDa) is indicated by dotted lines.
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closely that of sCJDMM1, whereas they are quite different from that of
human PrPSc type 2 associated with other subtypes of sCJD. Sequencing
analysis shows that the two main N termini of the PK-resistant PrPSc
associated with CWD in elk and with sCJDMM1 are residues 82 and 78
in both conditions, but slightly different from the N termini at residues
86 and 82 of the sCJDVV1-associated PK-resistant PrPSc fragment. The
identical N termini of the two major PrPSc PK-resistant fragments indi-
cate that both PrPSc species are cleaved by PK at the same sites and
therefore their protein cores have conformations that are similar using
this relatively crude criterion (22). The elk CWD PrPSc and the
sCJDMM1PrPSc species also have very similar characteristics according
to the conformational stability assay, a test that assesses the stability of
the PrPSc measured by the loss of PK-resistant PrPSc in molecules as a
function of treatment with increasing amounts of the denaturant
GdnHCl. However, substantial differences have emerged from the
determination of the glycoform ratios and mobility in two-dimensional
immunoblots. The ratios of the three bands representing diglycosylated,
monoglycosylated, and unglycosylated forms of PK-resistant PrPSc
show the overrepresentation of the diglycosylated band,which accounts
for 50% of the total PrPSc and the underrepresentation of the ungly-
cosylated band, which accounts for 20% of the total in both elk and
mule deer PrPSc. The glycoform pattern and ratio of CWD-associated
PrPSc is in basic agreement with an earlier report by Race et al. (36)
although they observed much great variability among individual ani-
mals. This glycoform ratio is also similar to that of BSE and vCJD (20, 34,
36–38). We have recently demonstrated that the type, glycoform pat-
tern, and ratio of elk PrPSc as reported here are reproducible upon trans-
mission to cervidized transgenic mice (39). In contrast, the glycoform
ratios observed in all forms of sCJD show an overrepresentation of the
monoglycosylated form that accounts for 50%, whereas between 20
and 30% each is accounted for by the other two forms. We found a
similar ratio of the PrPSc glycoforms in several CJD-affected big game
hunters who might have been exposed to CWD. These cases had the
genotype, PrPSc type, and disease phenotype of sCJD, strongly suggest-
ing that in these cases the CJD is likely sporadic and not acquired from
the consumption of CWD-contaminated cervid meat.
Two-dimensional immunoblots of PK-resistant PrPSc from CWD
and sCJDMM1 also demonstrate heterogeneity between the two pro-
files. The heterogeneity is likely to be in large part due to the difference
in the type and amount of glycans in the two glycosylated isoforms
present in PrPSc of sCJDMM1 and CWD. Although most of the heter-
ogeneity between the glycosylated forms can be attributed to the differ-
ent glycoform ratios, some is likely to be because of differences in elec-
trical charges that probably reflect distinct characteristics of the glycans
associated with PrPSc. However, heterogeneity persists even after deg-
lycosylation, indicating that there is additional diversity between PrPSc
from CWD and sCJDMM1, most likely related to the variations in
amino acid sequence.
There are thirteen variant amino acids between human PrP residues
78–231 and corresponding sequences of deer and elk. The differences
between elk and deer PrP sequences include one variant amino acid and
three polymorphic amino acids. The effect of these variations in the PrP
sequences is a change in the predicted pI values. It is predicted that in
the region corresponding to human PrP-(78–231), deer and elk PrP will
exhibit an increase in pI by 0.88 and 0.56, respectively, as comparedwith
human PrP. Therefore, deer PrP is most basic, followed by elk PrP and
human PrP. This is consistent with the result of two-dimensional
FIGURE 4. Conformational stability assay of PrPSc. A and B, Western blots of PK-resist-
ant PrPSc recovered from brain homogenates (A, cerebral cortex from CWD-affected elk;
B, frontal cortex from a case of sCJDMM1) following treatment with increasing concen-
trations of GdnHCl. C, the levels of PK-resistant PrPSc from CWD (filled diamond) or
sCJDMM1 (filled square) as a function of increasing concentrations of GdnHCl. Data
obtained by densitometry of Western blots probed with mAb 8H4, as shown in panels A
and B, are the average of independent experiments with samples from three elk with
CWD and four human brains with sCJDMM1 (mean S.D.).
FIGURE5.DeterminationofN-terminalPKcleavagesitesofPrPSc inCWDandCJDby
Edman sequencing. A, Edman sequencing of PK-resistant PrPSc purified from brains of
two elk was performed according to the procedure described by Parchi et al. (22). B,
schematic presentation of the full-length PrP polypeptide inclusive of residues 23–231
(upper). Dotted line signifies the PK cleavage sites in PrPSc. Wavy and zigzagged lines
indicate PK-sensitive and PK-resistant regions, respectively. Comparison of the N-termi-
nal PK cleavage sites of PrPSc in CWD and sCJD MM1, sCJDVV1, and iatrogenic CJDMM1
(lower). *, data fromParchi et al. (22). The twomajor PK-resistant fragments of CWDPrPSc
share the N termini with sCJDMM1 and iatrogenic CJDMM1 but not with sCJDVV1.
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immunoblots showing that deglycosylated PrPSc of deer migrated
toward most basic pI, followed by that of elk and human. Other causes
for heterogeneity may be related to the C-terminal glycolipid anchor
that may contain various numbers of sialic acids or the presence of
additional minor N-terminal cleavage sites, all of which may have con-
tributed to some overlapping two-dimensional spots of human, elk, and
deer PrPSc.
In conclusion, the parallel study of CWD that naturally occurs in elk
and deer and of prion disease occurring in humans with or without a
history of potential exposure to CWD reveals substantial differences in
the type and distribution of the histological lesions as well as in the
pattern of PrP immunohistochemistry. Similar findings have been
reported when natural BSE and vCJD were compared. However, in BSE
and vCJD the basic characteristics of PrPSc, such as protein type based
on the size of the PK-resistant PrPSc fragment, and the glycoform ratio
are similar. This is consistent with the notion that BSE PrPSc serves as
template for the human PrPSc associated with vCJD. In contrast,
although the size of the PK-resistant PrPSc fragment of CWD matches
most closely that of sCJDMM1, the glycoform ratio of CWD PrPSc is
different from that of the PrPSc associated with sCJDMM1 as well as all
non-familial human prion diseases except for vCJD. Furthermore,
CJDMM1 cases potentially exposed to CWD also had the same glyco-
form ratio as the other sporadic cases. These findings suggest that PrPSc
associated with CJDMM1 (as well as sCJDMV1 and sCJDVV1)3 in sev-
eral individuals (15) who were potentially exposed to CWD is not
derived from theCWDPrPSc and therefore in these individuals CJDwas
not acquired from CWD. This conclusion is in agreement with the
results of a recent experimental study on the transmissibility of elk
CWD to various transgenic mice (39). Although CWD could be trans-
mitted to transgenic mice expressing the elk PrP in a PrP knock-out
background following an incubation of 118–143 days, none of the trans-
genic mice expressing the human PrP manifested prion disease during
their lifespan following intracranial inoculation of CWD-affected brain
homogenate, indicating that there is a substantial species barrier for
transmission of elk CWD to humans. A recent report has shown that
CWD can be transmitted to squirrel monkeys, a non-human primate
(40). However, squirrel monkeys are very permissive to prions of differ-
ent species, including sheep scrapie to which humans are resistant.
Hence, squirrel monkeys may not be used as a suitable model of human
transmission of CWD. Although at present transmission of CWD to
humans may be doubtful, should it occur it is likely that the PrPSc asso-
ciated with this human prion diseasemay have a glycoform ratio similar
to that of CWD. However, the resulting histopathology and PrP immu-
nostaining patterns cannot be predicted. It is therefore important that
the study of cases affected by non-familial CJD includes detailed analysis
of the PrPSc characteristics.
Acknowledgments—We thank L. Ma and W. Wang for technical assistance
and D. Kofskey for histological and immunohistochemical staining.
REFERENCES
1. Williams, E. S., and Young, S. (1980) J. Wildl. Dis. 16, 89–98
2. Prusiner, S. B., Williams, E., Laplanche, J. L., and Shinagawa, M. (2004) in Prion
Biology and Diseases (Prusiner, S., ed) 2nd Ed., pp. 545–594, Cold Spring Harbor
Laboratory Press, Cold Spring Harbor, NY
3. Miller, M. W., and Williams, E. S. (2004) Curr. Top. Microbiol. Immunol. 284,
193–214
4. Williams, E. S. (2003) Clin. Lab. Med. 23, 139–159
5. Spraker, T. R., Zink, R. R., Cummings, B. A.,Wild,M.A.,Miller,M.W., andO’Rourke,
K. I. (2002) Vet. Pathol. 39, 110–119
6. Spraker, T. R., Zink, R. R., Cummings, B. A., Sigurdson, C. J., Miller, M. W., and
O’Rourke, K. I. (2002) Vet. Pathol. 39, 546–556
7. Liberski, P. P., Guiroy, D. C., Williams, E. S., Walis, A., and Budka, H. (2001) Acta
Neuropathol. (Berl). 102, 496–500
8. Williams, E. S., and Young, S. (1993) Vet. Pathol. 30, 36–45
9. Peters, J., Miller, J. M., Jenny, A. L., Peterson, T. L., and Carmichael, K. P. (2000) J. Vet.
Diagn. Investig. 12, 579–582
10. Sigurdson, C. J., Spraker, T. R., Miller, M. W., Oesch, B., and Hoover, E. A. (2001)
J. Gen. Virol. 82, Pt. 10, 2327–2334
11. Miller, M. W., and Williams, E. S. (2003) Nature 425, 35–36
12. Bunk, S. (2004) PLoS Biol. 2, E121
13. Williams, E. S., and Miller, M. W. (2002) Rev. Sci. Tech. 21, 305–316
14. Bartz, J. C., Marsh, R. F., McKenzie, D. I., and Aiken, J. M. (1998) Virology 251,
297–301
15. Belay, E. D., Maddox, R. A., Williams, E. S., Miller, M. W., Gambetti, P., and Schon-
berger, L. B. (2004) Emerg. Infect. Dis. 10, 977–984
16. Parchi, P., Giese, A., Capellari, S., Brown, P., Schulz-Schaeffer,W.,Windl, O., Zerr, I.,
Budka, H., Kopp, N., Piccardo, P., Poser, S., Rojiani, A., Streichemberger, N., Julien, J.,
Vital, C., Ghetti, B., Gambetti, P., and Kretzschmar, H. (1999) Ann. Neurol. 46,
224–233
17. Will, R. G. (2003) Br. Med. Bull. 66, 255–265
18. Head,M.W., Bunn, T. J., Bishop,M. T.,McLoughlin, V., Lowrie, S.,McKimmie, C. S.,
Williams, M. C., McCardle, L., MacKenzie, J., Knight, R., Will, R. G., and Ironside,
J. W. (2004) Ann. Neurol. 55, 851–859
19. Scott, M. R., Will, R., Ironside, J., Nguyen, H. O., Tremblay, P., DeArmond, S. J., and
Prusiner, S. B. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 15137–15142
20. Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C., Gowland, I., Collinge, J., Doey, L. J.,
and Lantos, P. (1997) Nature 389, 448- 450, 526
21. Zanusso,G., Liu, D., Ferrari, S., Hegyi, I., Yin, X., Aguzzi, A., Hornemann, S., Liemann,
S., Glockshuber, R., Manson, J. C., Brown, P., Petersen, R. B., Gambetti, P., and Sy,
M. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 8812–8816
22. Parchi, P., Zou, W., Wang, W., Brown, P., Capellari, S., Ghetti, B., Kopp, N., Schulz-
FIGURE 6. Immunoblots and glycoform ratios of PrPSc from CJDMM1 subjects with
possible exposure to CWD. Five cases of CJD in subjects with MM1 and a history of
potential exposure to CWD due to hunting and consumption of venison (hunter CJD
MM1) were used for analysis. Control cases were obtained from subjects with sCJDMM1
and sCJDMM2 according to the classification of Parchi et al. (16). Brain homogenates
were treated with PK, followed by SDS/PAGE (12% gel) and Western blotting using the
mAb3F4.A, immunoblot. The PrPSc bands detected represent diglycosylated (F),mono-
glycosylated (E), and unglycosylated () forms. The three PrPSc bands of the hunter
CJDMM1 are aligned with those of the sCJDMM1, but not with those of sCJDMM2, as
especially shownby thebandcontaining theunglycosylated form ().B, glycoform ratio
of PK-resistant PrPSc from the hunter CJDMM1 and sCJDMM1 cases. The ratios of digly-
cosylated, monoglycosylated, and unglycosylated forms of PrPSc in the hunter cases
were determined by densitometry of the corresponding immunoblots and were aver-
aged and expressed as percentage of the total (mean S.D.). Data for sCJDMM1 were
obtained from Parchi et al. (16).
PrPSc in CWD and CJD
FEBRUARY 17, 2006•VOLUME 281•NUMBER 7 JOURNAL OF BIOLOGICAL CHEMISTRY 4205
 
Schaeffer, W. J., Kretzschmar, H. A., Head, M. W., Ironside, J. W., Gambetti, P., and
Chen, S. G. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 10168–10172
23. Zou, W. Q., Capellari, S., Parchi, P., Sy, M. S., Gambetti, P., and Chen, S. G. (2003)
J. Biol. Chem. 278, 40429–40436
24. Peretz, D., Scott, M. R., Groth, D., Williamson, R. A., Burton, D. R., Cohen, F. E., and
Prusiner, S. B. (2001) Protein Sci. 10, 854–863
25. Zou, W. Q., Zheng, J., Gray, D. M., Gambetti, P., and Chen, S. G. (2004) Proc. Natl.
Acad. Sci. U. S. A. 101, 1380–1385
26. Bolton, D. C., Bendheim, P. E., Marmorstein, A. D., and Potempska, A. (1987) Arch.
Biochem. Biophys. 258, 579–590
27. Chen, S. G., Parchi, P., Brown, P., Capellari, S., Zou, W., Cochran, E. J., Vnencak-
Jones, C. L., Julien, J., Vital, C., Mikol, J., Lugaresi, E., Autilio-Gambetti, L., and Gam-
betti, P. (1997) Nat. Med. 3, 1009–1015
28. Parchi, P., Castellani, R., Capellari, S., Ghetti, B., Young, K., Chen, S. G., Farlow, M.,
Dickson, D. W., Sima, A. A., Trojanowski, J. Q., Petersen, R. B., and Gambetti, P.
(1996) Ann. Neurol. 39, 767–778
29. Safar, J., Wille, H., Itri, V., Groth, D., Serban, H., Torchia, M., Cohen, F. E., and
Prusiner, S. B. (1998) Nat. Med. 4, 1157–1165
30. Scott, M., Peretz, D., Ridley, R. M., Baker, H. F., DeArmond, S. J., and Prusiner, S. B.
(2004) in Prion Biology and Diseases (Prusiner, S., ed) 2nd Ed., pp. 434–482, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, NY
31. Will, R. G., Alpers, M. P., Dormont, D., and Schonberger, L. B. (2004) in Prion Biology
and Diseases (Prusiner, S., ed) 2nd Ed., pp. 629–671, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, NY
32. Ironside, J. W. (1996) Brain Pathol. 6, 379–388
33. Wells, G. A., and Wilesmith, J. W. (1995) Brain Pathol. 5, 91–103
34. Collinge, J., Sidle, K. C., Meads, J., Ironside, J., and Hill, A. F. (1996) Nature 383,
685–690
35. Gambetti, P., Kong, Q., Zou, W., Parchi, P., and Chen, S. G. (2003) Br. Med. Bull. 66,
213–239
36. Race, R. E., Raines, A., Baron, T. G.,Miller,M.W., Jenny, A., andWilliams, E. S. (2002)
J. Virol. 76, 12365–12368
37. Casalone, C., Zanusso,G., Acutis, P., Ferrari, S., Capucci, L., Tagliavini, F.,Monaco, S.,
and Caramelli, M. (2004) Proc. Natl. Acad. Sci. U. S. A. 101, 3065–3070
38. Parchi, P., Capellari, S., Chen, S. G., Petersen, R. B., Gambetti, P., Kopp, N., Brown, P.,
Kitamoto, T., Tateishi, J., Giese, A., and Kretzschmar, H. (1997)Nature 386, 232–234
39. Kong, Q., Huang, S., Zou,W. Q., Vanegas, D.,Wang,M.,Wu, D., Yuan, J., Zheng, M.,
Bai, H., Deng, H., Chen, K., Jenny, A. L., O’Rourke, K., Belay, E. D., Schonberger, L. B.,
Petersen, R. B., Sy, M. S., Chen, S. G., and Gambetti, P. (2005) J. Neurosci. 25,
7944–7949
40. Marsh, R. F., Kincaid A. E., Bessen, R. A., and Bartz, J. C. (2005) J. Virol. 79,
13794–13796
PrPSc in CWD and CJD
4206 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 7•FEBRUARY 17, 2006
 
